Researchers at MIT are subject to the Institute’s Conflict of Interest in Research Policy which supports compliance with Federal and sponsor-specific conflict of interest (COI) disclosure requirements. Anyone submitting a COI disclosure should first read the Institute's Conflict of Interest in Research Policy. Any questions about a potential COI or the COI policy should be discussed with the department, lab or center head or MIT’s COI Officer (firstname.lastname@example.org). We are here to help you.
Helpful Hints about your COI disclosure:
- Are some buttons grayed out on your MyCOI landing page? Here’s why!
- If an entity does not meet the definition of an SFI, be sure to inactivate it from the “View” box by choosing “SFI Entity (incl. INACTIVE)” before you begin revising your disclosure. This way, you only need to provide relationship details on those entities which are current SFI’s. Read more...
- The new COI regulations require the investigator to provide detail on how an SFI entity does or does not have a relationship to each research project so that the COI officer or another designated official, can make a determination of relatedness. In the past, that determination had been left to the investigator, therefore, if you had specified “none” or “no relationship” then there were no further questions, now, more details are required.
Streamlining the COI Disclosure process
Updated MIT COI Policy: effective late August 2013
MIT updated its COI policy in August 2013 in response to faculty feedback and new clarifications issued by the NIH on travel disclosure for PHS investigators. The travel policy change impacts PHS investigators only and coupled with a redesigned travel disclosure page, should relieve some administrative burden from Investigators. A summary of changes can be found here.
COI in the News
- Lauded public health researcher also worked for industry, revealing entanglements of science NEW!
- Reaching for Silicon Valley
- Breaking the seal on drug research
- NYU Researchers Arrested
- MIT professor Moniz sits on corporate boards; critics see potential for conflicts of interest